No development of additional platelet alloantibodies was observed during this platelet transfusion regiment. This study showed that transfusion of cross-match-compatible platelet units offers effective and safe management of platelet transfusion refractoriness (PTR). The finding of alloantibodies among cross-match-incompatible cases can be used as predictors for platelet donor selection.

In this study, we found alloimmunization against HLA class I, II and HNA in 4.63, 24.70 and 0.39%, respectively, in our female blood donors, indicating that the use of plasma containing blood products from parous female blood donors without HLA antibodies pre-testing may increase the risk of TRALI reaction. Although immunization against HNA seems to be a rare event in China, further observation is necessary to decide the necessity of HNA antibodies screening in our blood donors.

No abstract

Immune‐mediated thrombocytopenia is commonly caused by platelet‐reactive antibodies mostly against polymorphic structures residing on platelet glycoproteins such as human leucocyte antigen and human platelet antigen (HLA class I and HPA). In the Japanese population, some individuals do not express CD36 (CD36null also known as Naka) on the cell surface. Immunization of these individuals can lead to the development of CD36 isoantibodies (anti‐Naka) which play a role in the mechanism of platelet transfusion refractoriness, post‐transfusion purpura and fetal/neonatal alloimmune thrombocytopenia. Until today, however, little is known about the clinical relevance of CD36 deficiency and CD36 isoantibodies among other South‐East Asian populations. Therefore, multinational study was organised under the aegis of the ISBT to study the distribution of CD36 deficiency in this region.

MICA*063N has one nucleotide different from MICA*027 at position 184 (C→T) in codon 62 (CAG→TAG), resulting in a premature stop codon in exon 2.